

## Ovarian Cancer: Identifying and Managing Familial and Genetic Risk Committee meeting 9

**Date:** 01/02/2023

**Location:** Virtually via Zoom

**Minutes:** Confirmed

<b>Committee members present:</b>		
Alison Cameron (Chair)		(Present for notes 1 – 8)
Ranjit Manchanda (Topic Advisor)		(Present for notes 1 – 8)
Victoria Barber		(Present for notes 1 – 8)
Adam Brentnall		(Present for notes 1 – 7)
Rebecca Bowen		(Present for notes 1 – 8)
Melanie Davies		(Present for notes 1 – 6)
Gareth Evans		(Present for notes 1 – 8)
Judith Hayward		(Present for notes 1 – 8)
Tracie Miles		(Present for notes 1 – 8)
Glenn McCluggage		(Present for notes 1 – 8)
Fiona Robb		(Present for notes 1 – 8)
Adam Rosenthal		(Present for notes 1 – 8)
Lucy Side		(Present for notes 1 – 8)
Joanne Stanford		(Present for notes 1 – 8)
Vishakha Tripathi		(Present for notes 4 – 8)

<b>In attendance:</b>		
Katharina Dworzynski	Guideline Lead	(Present for notes 1 – 8)
Hayley Shaw	Project Manager	(Present for notes 1 – 8)
Nathan Bromham	Senior Systematic Reviewer	(Present for notes 1 – 8)
Laura Berg	Systematic Reviewer	(Present for notes 1 – 8)
Katriona O'Donoghue	Systematic Reviewer	(Present for notes 6 – 8)
Suhayl Kassam	Systematic Reviewer	(Present for notes 1 – 8)
Eric Slade	Senior Health Economist	(Present for notes 1 – 8)
Sarah Palombella	Senior Medical Editor	(Present for notes 1 – 8)
Olivia Waring	Senior Medical Editor	(Present for notes 1 – 4)
Adam Storrow	Resource Impact Lead	(Present for notes 1 – 8)

**Expert witness attendance**

Professor Alistair McGuire	Present for note 4
----------------------------	--------------------

**Apologies:**

Davina Moses	Committee member
Britta Stordal	Co-opted committee member
Mark Davies	Co-opted committee member
Emma Clegg	Information Scientist
Neil Ryan	Clinical Fellow
Steve Pilling	Clinical Advisor
Tara Chernick	Adoption and Implementation Manager
Nick O'Callaghan-Staples	Guideline Commissioning Manager

**1. Welcome, housekeeping, aims of the day and apologies**

The Chair welcomed the committee members and attendees to the 9<sup>th</sup> meeting on Ovarian Cancer: Identifying and Managing Familial and Genetic Risk.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the meeting objectives.

**2. Confirmation of matter under discussion, and declarations of interest**

The Chair asked everyone to verbally declare any interests that have risen since the last meeting. New interests were declared as noted below. Ranjit Manchanda and Gareth Evans were present throughout the committee meeting but were excluded from making decisions related to topics 4.1 and 4.3 due to a conflict arising from previously declared interests.

Name	Role	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Dr Adam Brentnall	Committee member	Direct non-financial professional and personal	UK National Screening Committee Research and Methodolo	January 2023	01/02/2023	Ongoing	Declare and participate, Agreed by GL and Chair

		interest	gy Group Member				– February 2023  Rationale : This interest is non-specific to the scope of the guideline.
<b>3. Minutes of the last meeting</b>							
The Chair asked the committee to confirm the minutes of the last meeting, and the committee confirmed no changes were required.							
<b>4. Morning presentations</b>							
<p>Olivia Waring, Senior Medical Editor, gave a presentation on Gendered language use.</p> <p>Eric Slade, Senior Health Economist, gave an update on the economic model for 4.1</p> <p>The Chair introduced Professor Alistair McGuire, Professor of Health Economics and Expert Witness, who presented on 6.1 and 6.2 giving an overview of the economic model related to surveillance (ALDO). The committee made changes to current recommendations and discussed the impact on recommendations.</p> <p>The Chair introduced Suhayl Kassam, Systematic Reviewer who presented on evidence review 8.2: ‘What pathological protocol for handling specimens from risk reducing surgery should be followed for risk-reducing surgery for women at increased risk of familial ovarian cancer?’</p>							
<b>5. Lay member forum</b>							
Lay members were given the opportunity to reflect and make any suggestions or comments to the other committee members.							
<b>6. Afternoon presentations</b>							
<p>The Chair introduced Eric Slade, Senior Health Economist who gave an update on the economic model for 8.1.</p> <p>The Chair introduced Laura Berg, Systematic Reviewer and Katharina Dworzynski, Guideline Lead, who led on edited recommendations for evidence review question 4.3.</p>							
<b>7. Questions and discussion</b>							
The committee discussed:							

- Economic model for 4.1
- Economic model related to surveillance for 6.1 and 6.2
- The evidence presented for evidence review question 8.2
- Economic model for 8.1
- The edited recommendations for evidence review questions 4.3

#### **8. Any other business and summary of actions**

Katharina Dworzynski summarised the actions and confirmed the topics for the next meeting.

No other business was discussed.

The Chair closed the meeting at 16:30.

**Date of next meeting:** 16/03/2023

**Location of next meeting:** Via Zoom.